News & Updates

Central obesity, as assessed by the waist-to-hip ratio (WHR), is very common in patients with axial spondyloarthritis (axSpA), particularly in women, reveals a recent study. This modifiable comorbidity may result in worse quality of life, worse disease activity, and greater impairment of functional ability.

Short-term tumour necrosis factor (TNF) inhibition with adalimumab falls short of producing improvements in patients with radiographic knee osteoarthritis, according to the proof-of-concept OKINADA trial presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.

The investigational drug ABX464, also known as obefazimod, helps reduce disease activity in patients with rheumatoid arthritis (RA), according to the results of a phase II trial. The 50-mg dose is well tolerated, while the higher dose is associated with mild-to-moderate adverse effects resulting in treatment discontinuation.

Pregnancies in women with rheumatic and systemic autoimmune diseases—including systemic lupus erythematosus, spondyloarthritis, and rheumatoid arthritis—pose significant health risks and are likely to lead to unfavourable outcomes, according to several studies presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.

Contrary to what current guidelines advocate, long-term use of corticosteroid works fine in older patients with rheumatoid arthritis (RA), suggests the much-anticipated GLORIA* trial presented at EULAR 2022.

In a phase II trial evaluating three doses of the high-affinity cereblon modulator iberdomide, the 0.45-mg dose demonstrated superiority over placebo for individuals with active, moderate-to-severe systemic lupus erythematosus (SLE).